PMID- 34848458
OWN - NLM
STAT- MEDLINE
DCOM- 20211210
LR  - 20211214
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 41
IP  - 12
DP  - 2021 Dec
TI  - Efficacy of a Novel Oral Chemotherapeutic Agent, TAS-102, Against Human Oral 
      Squamous Cell Carcinoma Cells.
PG  - 6039-6049
LID - 10.21873/anticanres.15423 [doi]
AB  - BACKGROUND: TAS-102 is effective against unresectable advanced or recurrent 
      colorectal and gastric cancer. However, its effect on oral squamous cell 
      carcinoma (OSCC) is still unknown. Here, we tried to clarify the possible effect 
      of TAS-102 against angiogenesis and proliferation of human OSCC cells. MATERIALS 
      AND METHODS: 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, 
      migration assay and mice xenograft models were used to determine the effect of 
      TAS-102 on growth and migration of OSCC. The activity of phosphorylated nuclear 
      factor kappa light-chain-enhancer of activated B-cells (NF-kappaB) (p-p65) in cells 
      was detected by immunocytochemistry. The expression of p-AKT serine/threonine 
      kinase 1 (p-AKT), p-p65, vascular endothelial growth factor (VEGF), fibroblast 
      growth factor (FGF2) and CD31 in mouse tumors were detected by 
      immunohistochemistry. RESULTS: TAS-102 significantly inhibited growth and 
      migration of OSCC both in vitro and in vivo. It suppressed the activity of NF-kappaB 
      in cells. TAS-102 down-regulated the expression of p-AKT, VEGF, FGF2 and CD31, 
      which was associated with reduced vascularization of HSC2 tumor lesions. 
      CONCLUSION: These findings suggest that TAS-102 might inhibit angiogenesis and 
      proliferation of OSCC cells.
CI  - Copyright (c) 2021 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Harada, Koji
AU  - Harada K
AD  - Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate 
      School of Medicine, Ube, Japan harako@yamaguchi-u.ac.jp.
FAU - Ferdous, Tarannum
AU  - Ferdous T
AD  - Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate 
      School of Medicine, Ube, Japan.
FAU - Mishima, Katsuaki
AU  - Mishima K
AD  - Department of Oral and Maxillofacial Surgery, Yamaguchi University Graduate 
      School of Medicine, Ube, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Combinations)
RN  - 0 (NF-kappa B)
RN  - 0 (Pyrrolidines)
RN  - 0 (trifluridine tipiracil drug combination)
RN  - QR26YLT7LT (Thymine)
RN  - RMW9V5RW38 (Trifluridine)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/*pharmacology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Proliferation/drug effects
MH  - Disease Models, Animal
MH  - Drug Combinations
MH  - Female
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Mice
MH  - Mouth Neoplasms
MH  - NF-kappa B/metabolism
MH  - Neovascularization, Pathologic/drug therapy
MH  - Pyrrolidines/administration & dosage/*pharmacology
MH  - Signal Transduction
MH  - Squamous Cell Carcinoma of Head and Neck
MH  - Thymine/administration & dosage/*pharmacology
MH  - Trifluridine/administration & dosage/*pharmacology
MH  - Xenograft Model Antitumor Assays
OTO - NOTNLM
OT  - NF-kappaB
OT  - TAS-102
OT  - anti-angiogenesis
OT  - oral squamous cell carcinoma
OT  - p-AKT
OT  - phosphorylated AKT
EDAT- 2021/12/02 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/12/01 06:05
PHST- 2021/08/12 00:00 [received]
PHST- 2021/10/08 00:00 [revised]
PHST- 2021/10/11 00:00 [accepted]
PHST- 2021/12/01 06:05 [entrez]
PHST- 2021/12/02 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
AID - 41/12/6039 [pii]
AID - 10.21873/anticanres.15423 [doi]
PST - ppublish
SO  - Anticancer Res. 2021 Dec;41(12):6039-6049. doi: 10.21873/anticanres.15423.